Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy
- 14 February 2011
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (9), 3719-3724
- https://doi.org/10.1073/pnas.1100349108
Abstract
Asian patients with chronic hepatitis C (CHC) are known to have better virological responses to pegylated (Peg) IFN-based therapy than Western patients. Although IL28B gene polymorphisms may contribute to this difference, whether favorable hepatitis C virus (HCV) kinetics during treatment plays a role remains unclear. We enrolled 145 consecutive Taiwanese patients with CHC receiving Peg-IFN α-2a plus ribavirin for the study. Blood samples were taken more frequently at defined intervals in the first 3 d. Peg-IFN was administered at week 1. It was then administered weekly in combination with daily ribavirin for 24 or 48 wk. A mathematical model fitted to the observed HCV kinetics was constructed, which could interpret the transient HCV titer elevation after Peg-IFN treatment. The results demonstrated a comparable viral clearance rate (c = 3.45 ± 3.73) (day−1, mean ± SD) but lower daily viral production rate (P = 106–1012) in our patients than those reported previously in Western patients. Of 110 patients with a sustained virological response (SVR), 47 (43%) had a transient elevation of viral titer within 12 h (proportion of 12 h/3 d: 44% in non-SVR vs. 70% in SVR; P = 0.029). Among 91 patients with available rs8099917 data, patients with the TT genotype had an early surge of viral titer after therapy and a higher SVR and viral clearance rate than those with the GT genotype. In conclusion, Taiwanese patients with CHC receiving Peg-IFN plus ribavirin therapy have a lower daily viral production rate than Western patients, and the rs8099917 TT genotype may contribute to the increased viral clearance rate and better virological responses in these patients.Keywords
This publication has 46 references indexed in Scilit:
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α‐2bJournal of Viral Hepatitis, 2008
- Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: Insulin resistance and response to antiviral therapyHepatology, 2007
- Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in TaiwanIntervirology, 2007
- Predictors of response of U.S. veterans to treatment for the hepatitis C virusHepatology, 2007
- Diagnosis, management, and treatment of hepatitis CHepatology, 2004
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002Hepatology, 2002
- Viral kinetics of hepatitis C: New insights and remaining limitationsHepatology, 2002
- Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis CJournal of Viral Hepatitis, 1996